WOOBURN GREEN, England, April 18, 2016 /PRNewswire/ --
Provides Patients With Important New Medicines
Martindale Pharma, the UK-based international specialty pharmaceutical company, today announced it has signed a new multi-year distribution and commercialisation agreement with Fannin Limited ("Fannin"), a leading supplier of pharmaceuticals to hospitals and pharmacies in Ireland and a subsidiary of DCC Vital.
Under the new agreement, Fannin will distribute and commercialise Martindale Pharma's products within the Emergency Care, Hospital-initiated Medicines and Opioid Addiction portfolios in Ireland. The deal builds on the long term relationship between the companies in Ireland which has seen Martindale Pharma's products take a significant market share through Fannin's commercial expertise.
Michael Harris, CEO of Martindale Pharma commented: "Northern Europe is a key focus for Martindale Pharma's international growth and we are delighted to announce this new agreement. Fannin has been a very strong partner for us and this new deal provides the opportunity to launch new products into Ireland to the benefit of Irish patients."
The product range includes methadone, selected Emergency Care sterile ampoule products, Noyada, Europe's first licensed oral liquid solution of captopril, Teglutik, a novel patented oral liquid formulation of riluzole and Prenoxad Injection, the world's first licensed presentation of naloxone specifically for use in a community/non clinical setting by a non-healthcare professional to reverse opioid overdose. Noyada and Prenoxad Injection are available under early access programmes.
About Martindale Pharma®
Martindale Pharma is a leading UK-based, international specialty pharmaceutical company providing essential medicines to over 28 countries around the world.
Our strategy is to build leading positions in defined business segments where there is a high unmet medical need and a demand for improved product presentations. Our focus is on Opioid Addiction, Emergency Care, Hospital-initiated Medicines, Ophthalmics and Unlicensed Medicines (also called "Specials").
With a strong UK presence with expertise in marketing hospital and specialty medicines, Martindale Pharma is recognised as a strategic partner to the NHS and other healthcare providers and supplying over 100 licensed products and with a track record of successful new specialty product launches.
The business also includes a rapidly growing international organisation currently centred on three geographical regions: Saudi Arabia and the Gulf Co-Operation Council territory, Australia and South East Asia and Northern Europe (focused on Scandinavia).
Martindale's supply chain is underpinned by our own modern, efficient UK manufacturing facility which enables us to develop and compete globally to supply high quality, specialty pharmaceuticals in sterile injection and oral liquid formats.
For further information visit our new website http://www.martindalepharma.co.uk
About Fannin Limited
Fannin Limited is a company with a strong history in the supply of innovative and quality medicines,devices and services. With a heritage dating back to 1829, it has significantly expanded over the past 10 years from being focused on the hospital sector, to now also having a substantial presence in the community pharmacy sector.
With a focus on acquisitive and organic growth, and employing over 300 employees, Fannin provides a wide range of Branded, Generic, Unlicensed and Specialty Pharmaceuticals across a wide range therapeutic areas and has become a leading supplier of medicines to both Hospital and Retail Pharmacies in Ireland.
In addition to providing experience in the Sales and Marketing of products to specialty areas, the products and services provided by Fannin are also backed up by dedicated support teams including customer service, logistics, quality control, pharmacovigilance and medical information.
Fannin is a subsidary of DCC Plc, a FTSE 100 listed international sales, marketing, distribution and business support services group, who employ over 10,200 people across 14 countries, and who reported revenues of £10.6 billion in their last financial year.
Media Contacts: Martindale Pharma Michael Clark Tel: +44 (0) 1628 551934 Hume Brophy Mary Clark, Hollie Vile, Elle Kress Tel : +44 (0) 207 862 6390
SOURCE Martindale Pharma